BSGI Molecular Breast Imaging Significantly Improves Breast Cancer Detection

Results from a multi-center patient registry, presented at a recent National Consortium of Breast Centers Annual Meeting, demonstrate that Breast-Specific Gamma Imaging (BSGI) also known as Molecular Breast Imaging (MBI) improves breast cancer detection when added to mammography and ultrasound in the breast clinic.

In this study, BSGI/MBI detected cancers in nearly 13% of patients who had negative or indeterminate mammograms and an unresolved diagnostic concern such as subtle changes in the mammogram, breast pain, a new breast lump, nipple discharge, etc. Another 4% of these patients had a high-risk lesion detected by BSGI/MBI. BSGI performed significantly better than ultrasound, detecting 92% of cancers compared to just 60% by ultrasound.

According to co-author Dr. Jean Weigert of Mandell and Blau MDs PC, New Britain, CT, “The primary advantage of ultrasound is that it does not use radiation, however, a negative ultrasound can still miss cancers. Our results demonstrate that in cases where mammography and ultrasound are negative or indeterminate, BSGI can still detect some cancers. The BSGI study does involve low doses of radiation, but the benefit of early cancer detection dwarfs the health risk from the radiation dose. In fact, there has never been a reported health impact from such low radiation doses and the benefit is evident in our data. Even according to the most conservative risk-models, the benefit outweighs the risk 680 to 1.”

Weill Cornell Medical Center offers BSGI/MBI.

 

Leave a Comment

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s